QIAGEN N.V.: QIAGEN to conduct an up to US$200 million share repurchase program
January 31, 2018 at 09:10 pm
Share
DGAP-Ad-hoc: QIAGEN N.V. / Key word(s): Share Buyback
QIAGEN N.V.: QIAGEN to conduct an up to US$200 million share repurchase program
31-Jan-2018 / 22:04 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Ad hoc Announcement according to Art. 17 Market Abuse Regulation
QIAGEN to conduct an up to US$200 million share repurchase program
Venlo, The Netherlands, January 31, 2018 - QIAGEN N.V. announces that its Managing Board, upon authorization of the Supervisory Board, has passed a resolution to exercise the authorization granted by the General Meeting of Shareholders on June 21, 2017, and to purchase shares in the Company up to a total of US$200 million (or the equivalent Euro amount thereof, in each case excluding transaction costs). Based on the closing price on January 30, 2018, this represents a repurchase volume of approximately 5.9 million shares. The repurchase program is scheduled to begin at the earliest on February 6, 2018, and to be completed on December 21, 2018, at the latest, or if the upcoming General Meeting of Shareholders will extend the authorization to repurchase shares, on June 30, 2019, at the latest. Details of the repurchase program will be announced before its actual commencement in line with Article 5 Section (1) and (6) of the EU regulation 596/2014 in conjunction with the regulatory technical standards adopted by the European Commission (so called Safe Harbour Regulation). Repurchased shares will be held in treasury in order to satisfy obligations from employee share-based remuneration plans.
John Gilardi, Tel: +49 2103 29 11711; ir@qiagen.com
Thomas Theuringer, Tel: +49 2013 29 11826 pr@qiagen.com
31-Jan-2018 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
Language:
English
Company:
QIAGEN N.V.
Hulsterweg 82
5912 PL Venlo
Netherlands
Phone:
+31 7735566 - 00
Fax:
+31 77 35566-58
E-mail:
qiagen@qiagen.com
Internet:
www.qiagen.com
ISIN:
NL0012169213
WKN:
A2DKCH
Indices:
TecDAX
Listed:
Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; London, Chicago, Nasdaq, SIX
Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
QIAGEN N.V. 
